
Claims

1. A compound of formula (IV):



or a pharmaceutically acceptable salt thereof, wherein:

X^1 is CH or CCH_3;

R^2 is –H or –F;

R^4 is –H or $–CH_3$; and

R^8 is –H or CH_3.

2. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein X^1 is CH.

3. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein R^2 is H.

4. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein R^4 is $-CH_3$.

5. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein R^8 is H.

6. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1 wherein the compound is selected from:

(1*R*,2*R*)-2-[4-(3-Methyl-1*H*-pyrazol-5-yl)benzoyl]-*N*-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazin-3-yl)cyclohexanecarboxamide;

(1*R*,2*R*)-*N*-(5-Methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazin-3-yl)-2-[4-(5-methyl-1*H*-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;

(1*R*,2*R*)-*N*-(5-Methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazin-3-yl)-2-[4-(1*H*-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide;

(1*R*,2*R*)-*N*-(4-Oxo-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazin-3-yl)-2-[4-(1*H*-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide;

(1*R*,2*R*)-*N*-(2-Methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazin-3-yl)-2-[4-(5-methyl-1*H*-pyrazol-3-yl)benzoyl]cyclohexanecarboxamide; and

(1*R*,2*R*)-*N*-(2-Methyl-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazin-3-yl)-2-[4-(1*H*-pyrazol-5-yl)benzoyl]cyclohexanecarboxamide.

7. A compound according to claim 1, which is (1*R*,2*R*)-2-[4-(3-Methyl-1*H*-pyrazol-5-yl)benzoyl]-*N*-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazin-3-yl)cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 1, which is (1*R*,2*R*)-2-[4-(3-Methyl-1*H*-pyrazol-5-yl)benzoyl]-*N*-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrazin-3-yl)cyclohexanecarboxamide.

9. A pharmaceutical composition comprising a compound according to any of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, diluent, or excipient.

10. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, for use as a medicament.

11. Compound for use according to claim 10, wherein the use is for the treatment or prophylaxis of a disease selected from cardiovascular disease, chronic kidney disease, type II diabetes mellitus and complications of type II diabetes mellitus, respiratory inflammatory disease and complications associated therewith, renal inflammatory and vascular diseases and complications associated with renal disease, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

12. Compound for use according to claim 10 or claim 11 wherein the use is for the treatment of cardiovascular disease.